Compugen Ltd
NASDAQ:CGEN
Intrinsic Value
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. [ Read More ]
The intrinsic value of one CGEN stock under the Base Case scenario is 1.74 USD. Compared to the current market price of 1.91 USD, Compugen Ltd is Overvalued by 9%.
Valuation Backtest
Compugen Ltd
Run backtest to discover the historical profit from buying and selling CGEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Compugen Ltd
Current Assets | 114.6m |
Cash & Short-Term Investments | 50.7m |
Receivables | 63.5m |
Other Current Assets | 365k |
Non-Current Assets | 6.8m |
Long-Term Investments | 3m |
PP&E | 2.5m |
Other Non-Current Assets | 1.2m |
Current Liabilities | 26.3m |
Accounts Payable | 14.5m |
Accrued Liabilities | 632k |
Other Current Liabilities | 11.1m |
Non-Current Liabilities | 29.5m |
Other Non-Current Liabilities | 29.5m |
Earnings Waterfall
Compugen Ltd
Revenue
|
33.5m
USD
|
Cost of Revenue
|
-2m
USD
|
Gross Profit
|
31.5m
USD
|
Operating Expenses
|
-44.4m
USD
|
Operating Income
|
-13m
USD
|
Other Expenses
|
-5.8m
USD
|
Net Income
|
-18.8m
USD
|
Free Cash Flow Analysis
Compugen Ltd
CGEN Profitability Score
Profitability Due Diligence
Compugen Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Compugen Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
CGEN Solvency Score
Solvency Due Diligence
Compugen Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Compugen Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CGEN Price Targets Summary
Compugen Ltd
According to Wall Street analysts, the average 1-year price target for CGEN is 5.44 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.
Shareholder Return
CGEN Price
Compugen Ltd
Average Annual Return | 9.13% |
Standard Deviation of Annual Returns | 97.46% |
Max Drawdown | -97% |
Market Capitalization | 170.4m USD |
Shares Outstanding | 89 530 200 |
Percentage of Shares Shorted | 2.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Contact
IPO
Employees
Officers
The intrinsic value of one CGEN stock under the Base Case scenario is 1.74 USD.
Compared to the current market price of 1.91 USD, Compugen Ltd is Overvalued by 9%.